Basilea präsentiert auf ASCO GU Symposium Dosisfindungs-Ergebnisse für Derazantinib/PD-L1-Checkpoint-Inhibitor-Kombination aus FIDES-02-Studie für Patienten mit soliden Tumoren

NEXT STORY
North America Sports Medicine Market 2020-2030: Consistent Innovation of New Products and Treatment Modalities
PREV STORY
The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis

Phase 3 study follows positive 16-weeks Phase 2 data and further improvement in efficacy ...

author_avatar
NASDAQ Market News

Bone Therapeutics announces the appointment of Dr. Miguel Forte as CEO to lead the Company into the next phase of development

author_avatar
NASDAQ Market News

G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: ...

author_avatar
NASDAQ Market News